3SOF

REALLY showing my newbieness here, but what exactly is a reverse split and how does it affect one's holdings? Thanks.

Michael

9 OUT OF TEN 10 TIMES, after the reverse split, you'll lose....unless it's kmart

  On the big boards, occaisionally one, a R/S, such as SHLD you refered to, will be beneficial to the PPS...but OTC/pinks, I would say it is closer to 100% bad news that causes a PPS death spiral....if anybody has an example of a OTC/pinky that has had a R/S and the PPS went up, I would appreciate hearing about it....otherwise, if I even hear a rumor of R/S in pennyland, I will always RFTD. 

I was out all day and just got in.  What a pisser!  My largest holding cut in half.  Ouch!

I was in their website the other day and noticed a PR from July 2005 stating they are "only weeks ago from move to OTCBB."  That should've been another red flag, but I held on.

I can't see this doing anything good in the near future.....maybe in the next 1-2 years.  I'm too impatient for that.  Can't type what I'm thinking, too nasty.

I'm ready to RFTD as well.

I'm not in it and don't plan getting back in it...the red flags, begiinning w/ excon lawyer Evans on the board, mounted quickly when I began looking closely at the company and I exited. I began just playing the runup, getting in and out, but stayed too long the last time. From here, after an R/S announcement, here's my uneducated thoughts  if I were still in. It could keep going down from here...alot of people are very upset...but if another PR or two presplit dangles some more carrots, it may get a bounce...but I'd definitely exit before the split....after that it's downhill fast, unless Warren Buffet takes over.  Hope everyone gets out in time with something.  I learned some penny lessons here. 

CALIMESA, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Ingen Technologies, Inc.
(OTC: IGTN), a medical device manufacturer of OxyAlert(TM), OxyView(TM), Secure
Balance(TM), and Pure Produce(TM), announces that the third-quarter earnings and
profits continue to increase.

The 3rd qtr-2005 total deposits were $1,274,903.50, with gross expenses of
$779,421.76.  At the end of the 3rd qtr-2005, IGTN cash reserves as of 08/31/05
were approximately $ 500,000.  The deposits included Secure Balance(TM) sales of
$497,342.63, and the sale of common stock of $777,560.87. The common stock was
sold pursuant to a 504 Registration filed in Maryland and Texas.  Expenses
included large sums invested into R&D for the progression of OxyAlert(TM) and
OxyView(TM), as well as a national advertising campaign for Secure Balance(TM).


Commenting upon this action, Ingen CEO/Chairman Scott Sand said: "The company is
very focused and on-track.  Attorney Pete Wilke (Good Standing Member of the
California Bar Association) is very close to finalizing the SEC filings, and is
prepared to move IGTN to the OTCBB once the SEC has approved the company as a
reporting entity."

The Secure Balance(TM) sales indicate that IGTN is on target of reaching $2M in
total sales of this product line by May 31, 2006.  "With the effective national
advertising campaign for Secure Balance(TM) it is very likely that we would
exceed our target," said Chris Wirth, Director of IGTN.

So here is news on the R/S....but, is this that bad in this case?

Is it possible this stock could still rise in price, Sands sounds like this will restore the share price?

I'm still holding..it is actually useless for me to sell at the current price.

2005-10-12 07:15:04 
Ingen Technologies, Inc. Releases President's Letter to Investors 

--------------------------------------------------------------------------------


CALIMESA, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Ingen Technologies,
Inc. (OTC: IGTN), a medical device manufacturer of OxyAlert(TM), OxyView(TM),
Secure Balance(TM), and Pure Produce(TM), announces the release of the
President's Letter To Investors.

Dear Shareholders and Members of the Investment Community:
As Chairman / CEO and founder of Ingen Technologies, Inc. ("Ingen" or the
"Company"), it is important to have this opportunity to communicate with you,
as several events have made it timely to do so.
In regards to the 40-1 Reverse Stock Split That Has Been Proposed By the
Board: The Board of Directors ("Board") of Ingen recently voted unanimously to
recommend to shareholders a 40-1 reverse stock split of its outstanding common
shares. This would decrease the number of outstanding common shares from
approximately 490,000,000 shares now to about 12,250,000. The Board also
voted to decrease the number of authorized common shares from 500,000,000
presently to 100,000,000.In addition, the Board (and our two preferred shareholders) has approved a
resolution (contingent upon shareholder approval of the above actions with
respect to the common shares) that modifies the rights and conditions of our
preferred shares as well. This resolution provides that all preferred shares
are convertible into common shares. It mandates a 3-1 reverse split of the
preferred shares; from just under 40,000,000 issued preferred shares to
approximately 13,333,000 issued preferred shares. It reduces the current
convertability feature from one preferred share to ten common shares to a
one-for-one ratio. It allows for one vote per share instead of 15 votes per
share. The number of authorized convertible preferred shares remains at
40,000,000.The Board's rationale is sound and was based on the following facts and
considerations. During the last half of our 5/31/05 fiscal year, it became
necessary to raise capital from external sources to provide the liquidity
required to fund the costs to develop OxyView(TM) and OxyAlert(TM) until our
new products start contributing cash flow in 2006 (calendar). We elected to
sell stock to procure these funds, rather than issue debt, because it was less
difficult to do and it avoided burdening our balance sheet. The accompanying
consequence was to increase our common shares outstanding very substantially,
which caused dilution to our earliest shareholders and contributed to a
reduction in our share price.Nonetheless, both the Board and I believe the implicit trade-off was
necessary and that it will prove to have highly constructive long-term results
for our shareholders for several reasons.
* The 40-1 reverse stock-split of our common shares changes our capital
structure which does not affect the operational fundamentals of the
Company, nor does it decrease in any way the proportionate ownership
percentage of each common shareholders investment. The proposed
changes in our preferred share structure is reflective of the Board's
desire to maintain fairness and a reasonable capital structure for the
benefit of all our shareholders as we continue to grow our business by
attempting to attract additional capital investment and increase our
sales and available product lines.

* When a stock's share price dips to very low levels (in absolute
terms), as ours has recently done, it is typical for investors to
anticipate that a reverse stock split might be forthcoming. This
discounting process by the stock market usually causes a decrease in
the price of the shares and may be beyond the power of management's to
counter. This process appears to have already happened to some extent
in the case of Ingen's share price.

* The 40-1 reverse common stock split (which we expect to be approved)
should raise our share price to a much higher absolute level than it
has recently been trading; perhaps by as much as 40 times. It is
essential to have a higher per share price in order to be able to
obtain future financing from professional providers of funds and
institutional investors. This is an avenue that is seldom available
when a corporation's shares are selling for pennies (literally).
Further, the equity "cushion" that we have obtained could also become
the basis for subsequent issuance of debt -- which typically has the
lowest cost of capital.
* The resulting anticipated higher absolute stock price level should
reduce some of the extreme price volatility (as measured in percentage
terms) that our shares have experienced, especially recently when they
have been selling below $0.05 per share.
In short, we feel strongly that Ingen's decision to sell equity in FY2005,
even though it made a subsequent reverse stock split virtually necessary, was
a wise and constructive strategic choice for the Company. Our shareholders
will be required to vote on the proposed 40-1 reverse stock split and we
expect them to collectively affirm this step because of its overwhelming
merit.
Special Shareholders' Meeting to Vote on 40-1 Reverse Proposal, et al

Date: Monday, October 31, 2005 Telephone: (909) 790-7180
Hour: 9:00 AM (Pacific Time)Place: Ingen Technologies, Inc. Office
35193 Avenue A -- Suite C
Yucaipa, CA 92399
By law, given our particular circumstances, shareholders must vote to
approve the Board's reverse stock split proposal and reduction in authorized
common shares. Assuming approval, the reverse stock split and authorized
share reduction and its effect on the share capitalization will become
effective on the date of the vote.Shareholders are cordially invited to attend this Special Shareholders'
Meeting where they can vote, meet management, and ask questions.
Initial Discussions with Prospective Investment Bankers Are Encouraging
In order to fully fund our expanding product line, and its expected strong
revenue growth over time, additional external capital will be required. We
have had discussions with some prospective investment bankers. Although the
Company does not yet have any firm financing commitment at this time, we are
encouraged by their initial reactions and degree of interest, both of which
are conditional upon the 40-1 reverse split, et al, occurring.
Production Scheduled For Two New Products in 1Q2006.
Ingen's core corporate competency is the marketing of sophisticated
bio-medical equipment to niche markets. Therefore, it is of great importance
to note that Ingen's two new products -- OxyView(TM) and OxyAlert(TM) -- are
scheduled to go into production, by second parties, in early 2006 (calendar).
This is a major forthcoming event for Ingen, as it should contribute to a
significant increase in revenues and help to create a positive cash flow and
increased share value.It is my opinion that Ingen is on the cusp of posting positive and
accelerating financial results, eventually leading to attractive gains in
shareholder value. To those of you who are already shareholders, I want to
thank you for the confidence you have expressed in the Company's outlook, and
in me, by investing in Ingen shares. To those of you who are prospective
investors, I encourage you to consider investing in our shares. I like to
think that Ingen is a promising microcap company whose best days lie ahead. I
look forward to the challenge of leading Ingen to capitalize on its appealing
opportunities, fed by an aging and increasing population and serviced by our
technologically advanced products, which have competitively attractive
features.
Finally, our Investor relations program and resources have expanded so we
encourage you to contact us at the number listed below to learn more about
Ingen and to stay abreast of Ingen's developments.
Respectfully,

Scott R. Sand
Chairman / CEO
Ingen Technologies, Inc.

About Ingen Technologies, Inc.
Ingen Technologies, Inc. is a public company trading under
Nasdaq OTC: IGTN, which has been in business since 1999. IGTN is a medical
device manufacturer and a growth-oriented company that owns US patent(s),
trademarks, and proprietary medical products.
The Company's flagship product is OxyAlert(TM), a second-generation design
of the Company's BAFI(TM) product line. Both of these products have been
issued two US Patents: Patent No. 6,137,417 issued on October 24, 2000 and
Patent No. 6,326,896 issued on December 4, 2001. Both of these products are
low-oxygen safety warning devices used on remote oxygen cylinders for
patients, commercial aircraft, military transport, and fire and safety
equipment. OxyAlert(TM) technology encompasses the use of digital sensing and
RF frequency transfer so that care givers can access a hand-held remote to
monitor the actual oxygen level of any oxygen cylinder at a reasonable
distance.
The newest product, OxyView(TM), has a patent pending, and is a pneumatic
gauge that provides visual safety warning of oxygen flow to hospitalized
patients. This product enhances the safety, assurance and accuracy of
hospitalized patients being administered oxygen from any source. OxyView(TM)
is a lightweight pneumatic gauge that is attached to the oxygen tubing just
below the neck. It informs the nursing staff of oxygen flow rate near the
patient. It could quickly inform the hospital staff of any leak or inaccuracy
between the delivery source and the patient.
The Secure Balance(TM) product is a private-label product that includes a
vestibular function testing system and balance therapy system. The vestibular
function testing system is manufactured by Interacoustics LTD. in Denmark and
is referred to as the VNG. The balance therapy system is manufactured by
SportKAT(R), Inc. in San Diego, California. The Secure Balance(TM) program
provides equipment, education and training about balance and fall prevention
to physicians and clinicians worldwide.
The Pure Produce(TM) product is a continuing research & development
program currently under design. This program uses hydroponics technology to
grow various plants without the use of soil, fertilizer and water consumption.
The Company anticipates entering the nutriceutical and pharmaceutical markets
over the next two years.
"Our team of professionals has developed our medical products for the
ever-increasing elderly population. Our products are superior to any of our
competition and they allow for effective medical product availability to
seniors, and at the same time the increasing senior population allows for a
steady growth in sales and profits," said Scott Sand, CEO & Chairman of Ingen
Technologies.
For more information, visit www.ingen-tech.com

Investor Relations Contact:

Scott R. Sand, C.E.O. & Chairman
Ingen Technologies, Inc. - Administrative Office
35193 Avenue "A", Suite-C
Yucaipa, California 92399
Phone: (800) 259-9622 or (951) 675-3266
Fax: (800) 777-1186 or (909) 795-6340
Email: [email protected]

 I think that if a legit company expects to have any respect in the investing community they are going to have to do something about the crazy float they have and the (sub?)penny price they are selling for. Unfortunately, too often the reverse split has been used by unscrupulous companies for their own gain and it has gotten a bad reputation, but how else are they going to manage a float of 1/2 billion shares.  The price of this stock has already plummeted but that doesn't mean it can't go further because its all about how the r/s is perceived by the public.
So, the real question is, can this company become what it says it can become? A profitable business? If so, then even at this price, its a bargain. If not, then its just more (expensive) toilet paper.   I thing GZFX may have the same problem.  They announced a deal with Circuit City that can really work out great for them but as long as they have this enormous float and a sub-penny price, who is going to take them seriously?

So did everyone lose interest in IGTN now? Sure looks like a bargain now considering the fundamentals.

I bought a little amount of this

Reasons:

1. MACD getting positve
2. volume Increase
3. last candle looks like a hammer
4. rsi at bottom

good news

Ingen Technologies, Inc. Files 10-KSB on Edgar Next Week
Friday October 28, 7:15 am ET


CALIMESA, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Ingen Technologies, Inc. (OTC Bulletin Board: IGTN - News), a medical device manufacturer of OxyAlert(TM), OxyView(TM), and Secure Balance(TM), announces the SEC Filing schedule to become a reporting company and move to the OTCBB.
ADVERTISEMENT


Ingen Technologies, Inc., merged into Creative Recycling Technologies, Inc (CRTZ), a Georgia corporation, in March of 2004. The company changed its name to Ingen Technologies, Inc. (OTC: IGTN - News) shortly thereafter. CRTZ commenced periodic reporting under the Securities Exchange Act of 1934 in 1996 and ceased reporting in 1998.

The Securities and Exchange Commission has been in contact with the company attorney, Peter Wilke and the company is prepared to bring the periodic reporting up to date.

Attorney Peter Wilke stated: "We have committed to filing our fiscal year 2005 (ending May 31, 2005) 10-KSB on EDGAR no later than November 4, 2005. We have stated that we will file our fiscal year 2004 10-KSB and first quarter of fiscal year 2006 10-QSB in November of this year. We have stated that we will provide a schedule for filing our quarterly reports for fiscal years 2004 and 2005 in December."

"The company continues to generate revenues with the Secure Balance(TM) products. We will have a working prototype of OxyView(TM) and OxyAlert(TM) next month, at such time we will commence tooling and preparation for production of these products. The first production models of OxyView(TM) and OxyAlert(TM) will be evaluated by the Food and Drug Administration for issuance of a 510(k) to allow the company to market the devices within interstate commerce. We look forward to a bright future and prosperous year ahead," said Scott Sand, CEO and Chairman of Ingen Technologies, Inc.

About Ingen Technologies, Inc.

From Shareholders meeting.

This is from a post I found on Stockspot from someone who attended the meeting. It's more information than I've seen so far on this board.

"Yes I did go to the meeting today, and I was surpised with such a turnout (standing room only, if you got there late)
The CEO says reverse split was needed to fund production of the oxy-alert,oxy-view, and pure produce. He is going to use his shares to gain 8 million in funding
There will be a demonstration on th oxy products at the end of november.
They are gaining sales with secure balance, and stepping up advertising.
they were very confident with thier plans.(the pure produce facilities will be in so california)
He explained everything to the shareholders(he had all the votes that were mailed in, all the letters,all the signed documents)
Everybody voted, they tallied up the votes that were mailed, and the majority vote yes on all three issues.(to move the company forward)

He was confident that shareholder value will be restored.
He said infermed was still going to play a big part in IGTN'S future growth.

I asked him about your question about buying back shares ..he said after products come to market, that would be considered.
He wants to maintain a low float (to keep control of the daytraders and the MM'S)

He annouced a pr for tomorrow, at the meeting.And we will see IGTN on edger by friday.

I am only passing along what was presented in the meeting. so please don't kill the messenger.
I will hold my position. I was satified with the plan. the people who I met were very professional and focused.

I will pass on any information I can..I lost almost a full day of my business and the gasoline,because I wanted to see what was going on there today.

ket1390, Thanks for the feedback.
Applaud is in order for your work on this.
I'm still in, I haven't gave up the ship.
Getting a nice move today.

Press Release Source: Ingen Technologies, Inc.


Majority Shareholders Vote
Tuesday November 1, 7:15 am ET 
- Overwhelming Support for the Reverse Split -


CALIMESA, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Ingen Technologies, Inc. (OTC: IGTN - News), a medical device manufacturer of OxyAlert(TM), OxyView(TM), and Secure Balance(TM), announces the shareholder approval of a 40-1 reverse split.


On Monday, October 31, 2005, at 9:00am PST, the company conducted a Special Shareholder Meeting regarding the vote to approve the Resolution dated October 11, 2005. The Chairman & CEO, Scott Sand, promptly called the meeting to order. Sand presented a 2 hour presentation of the company's progress, including extremely detailed information about product development, audited financial information, accounting and operations. Preceding the 2 hour presentation, Mr. Sand opened the meeting to questions and comments.

All of the shareholders in attendance unanimously voted "yes" on all three of the items of the agenda. Further, all of the votes were counted, including the votes that were mailed and sent by facsimile. Without any of the votes from the founders and/or Officers/Directors, there were 13,083,000 "yes" votes and 9,600,000 "no" votes. With all of the shareholder votes, including the founders, Officers and Directors, the ratio of "yes" to "no" votes was 8:1.

"The majority of shareholders have spoken and have shown the confidence they have in our management and this company. The company is now positioned to be a successful reporting company on the OTCBB," said Scott Sand, CEO & Chairman.

"With the reverse split behind us, this opens doors for new investors and continued forward growth of this company," said Thomas Neavitt, CFO. Further, Neavitt stated, "The Company is on schedule to file the first of several SEC filings on EDGAR on or before this Friday."

About Ingen Technologies, Inc.

Ingen Technologies, Inc. is a public company trading under NASDAQ OTC:IGTN, which has been in business since 1999. IGTN is a medical device manufacturer and a growth-oriented company that owns US patent(s), trademarks, and proprietary medical products.

The Company's flagship product is OxyAlert(TM), a second-generation design of the Company's BAFI(TM) product line. Both of these products have been issued two US Patents: Patent No. 6,137,417 issued on October 24, 2000 and Patent No. 6,326,896 issued on December 4, 2001. Both of these products are low-oxygen safety warning devices used on remote oxygen cylinders for patients, commercial aircraft, military transport, and fire and safety equipment. OxyAlert(TM) technology encompasses the use of digital sensing and RF frequency transfer so that care givers can access a hand-held remote to monitor the actual oxygen level of any oxygen cylinder at a reasonable distance.

The newest product, OxyView(TM), has a patent pending, and is a pneumatic gauge that provides visual safety warning of oxygen flow to hospitalized patients. This product enhances the safety, assurance and accuracy of hospitalized patients being administered oxygen from any source. OxyView(TM) is a lightweight pneumatic gauge that is attached to the oxygen tubing just below the neck. It informs the nursing staff of oxygen flow rate near the patient. It could quickly inform the hospital staff of any leak or inaccuracy between the delivery source and the patient.

The Secure Balance(TM) product is a private-label product that includes a vestibular function testing system and balance therapy system. The vestibular function testing system is manufactured by Interacoustics LTD. in Denmark and is referred to as the VNG. The balance therapy system is manufactured by SportKAT®, Inc. in San Diego, California. The Secure Balance(TM) program provides equipment, education and training about balance and fall prevention to physicians and clinicians worldwide.

The Pure Produce(TM) product is a continuing research & development program currently under design. This program uses hydroponics technology to grow various plants without the use of soil, fertilizer and water consumption. The Company anticipates entering the nutriceutical and pharmaceutical markets over the next two years.

"Our team of professionals has developed our medical products for the ever-increasing elderly population. Our products are superior to any of our competition and they allow for effective medical product availability to seniors, and at the same time the increasing senior population allows for a steady growth in sales and profits," said Scott Sand, CEO & Chairman of Ingen Technologies.


     For more information, visit www.ingen-tech.com

     Investor Relations Contact: Scott R. Sand, C.E.O & Chairman
                                 Ingen Technologies, Inc. -
                                  Administrative Office
                                 35193 Avenue "A", Suite-C
                                 Yucaipa, California 92399
                                 Phone: (800) 259-9622 or (909) 790-7180
                                 Fax: (800) 777-1186 or (909) 795-6340
                                 Email: [email protected]

                                 A Member of the Better Business Bureau
                                 A Member of the Chamber of Commerce
                                 A Licensed Business in the City of Yucaipa

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements that are made pursuant to "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ will be set forth in the company's periodic filings (the first of which, since reporting ceased in 1998, will be filed shortly) with the U.S. Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: Ingen Technologies, Inc.

thanks setravis

i think everyone sold on the way down.....i bought 130 000 at 0.0052...as macd and fast stockastics are bullish....i see it go up just dont know the influence of the reverse split...

Any thoughts ?